{"id":127305,"date":"2021-09-05T05:58:37","date_gmt":"2021-09-05T05:58:37","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=127305"},"modified":"2021-09-05T05:58:37","modified_gmt":"2021-09-05T05:58:37","slug":"anti-parkinson-drugs","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/","title":{"rendered":"Anti-Parkinson drugs"},"content":{"rendered":"

Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.<\/p>\n

\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-127305","post","type-post","status-publish","format-standard","hentry","category-a"],"yoast_head":"\nAnti-Parkinson drugs - Definition of Anti-Parkinson drugs<\/title>\n<meta name=\"description\" content=\"Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti-Parkinson drugs - Definition of Anti-Parkinson drugs\" \/>\n<meta property=\"og:description\" content=\"Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-05T05:58:37+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/\",\"name\":\"Anti-Parkinson drugs - Definition of Anti-Parkinson drugs\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2021-09-05T05:58:37+00:00\",\"dateModified\":\"2021-09-05T05:58:37+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti-Parkinson drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti-Parkinson drugs - Definition of Anti-Parkinson drugs","description":"Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/","og_locale":"en_US","og_type":"article","og_title":"Anti-Parkinson drugs - Definition of Anti-Parkinson drugs","og_description":"Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/","og_site_name":"Glossary","article_published_time":"2021-09-05T05:58:37+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/","name":"Anti-Parkinson drugs - Definition of Anti-Parkinson drugs","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2021-09-05T05:58:37+00:00","dateModified":"2021-09-05T05:58:37+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"Drugs that address an imbalance between the primary neurotransmitters dopamine and acetylcholine. Parkinson disease is caused by an imbalance of the two neurotransmitters responsible for transmitting nerve impulses from the brain to the muscles. One group of anti-Parkinson drugs works by stimulating production of dopamine in the brain, sup\u00ac plying the substance from which it is formed (levodopa) to be converted to dopamine in the brain. Dopamine levels can also be increased by reducing the breakdown of dopamine in the brain or by stimulating its release.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/anti-parkinson-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Anti-Parkinson drugs"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/127305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=127305"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/127305\/revisions"}],"predecessor-version":[{"id":127306,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/127305\/revisions\/127306"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=127305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=127305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=127305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}